STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Intercept Pharmaceuticals to Participate in Piper Sandler’s 34th Annual Healthcare Conference on December 1, 2022 

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Rhea-AI Summary

MORRISTOWN, N.J., Nov. 22, 2022, Intercept Pharmaceuticals (Nasdaq: ICPT) announced that Jerry Durso, President and CEO, and Andrew Saik, CFO, will participate in a fireside chat at Piper Sandler’s 34th Annual Healthcare Conference on December 1, 2022. The chat is scheduled from 2:00 p.m. to 2:25 p.m. ET, and interested investors can register through their representatives to attend. Intercept specializes in developing therapeutics for progressive non-viral liver diseases, including primary biliary cholangitis and nonalcoholic steatohepatitis.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

MORRISTOWN, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, and Andrew Saik, Chief Financial Officer of Intercept, will participate in a fireside chat at Piper Sandler’s 34th Annual Healthcare Conference, taking place in person on Thursday, December 1, 2022. The Company will also conduct meetings with investors.

Intercept's fireside chat will take place from 2:00 p.m. – 2:25 p.m. ET. To view the fireside chat, please register for the Piper Sandler 34th Annual Healthcare Conference by contacting your representative. Investors attending the conference who wish to meet with the Intercept management team, please reach out to your representative or contact Nareg Sagherian

About Intercept 
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and severe alcohol-associated hepatitis (sAH). For more information, please visit www.interceptpharma.com or connect with the Company on Twitter and LinkedIn. 

Contact 
For more information about Intercept, please contact: 

Investor inquiries: investors@interceptpharma.com 
Media inquiries: media@interceptpharma.com 


FAQ

What is the date and time of Intercept's fireside chat at Piper Sandler’s Healthcare Conference?

Intercept's fireside chat is scheduled for December 1, 2022, from 2:00 p.m. to 2:25 p.m. ET.

Who will represent Intercept Pharmaceuticals at the Piper Sandler conference?

Jerry Durso, President and CEO, and Andrew Saik, CFO, will represent Intercept Pharmaceuticals.

How can investors view the fireside chat for Intercept Pharmaceuticals?

Investors can view the fireside chat by registering through their representatives for the Piper Sandler 34th Annual Healthcare Conference.

What is Intercept Pharmaceuticals focused on?

Intercept Pharmaceuticals focuses on developing therapeutics for progressive non-viral liver diseases.

What diseases does Intercept Pharmaceuticals aim to treat?

Intercept aims to treat primary biliary cholangitis, nonalcoholic steatohepatitis, and severe alcohol-associated hepatitis.
Intercept Pharmaceuticals Inc

NASDAQ:ICPT

ICPT Rankings

ICPT Latest News

ICPT Stock Data

40.45M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US